Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings PharmaCorp Rx Inc.: Strengths and Weaknesses

Highlights: PharmaCorp Rx Inc.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: PharmaCorp Rx Inc.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50 times its estimated earnings per share for the ongoing year.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

PharmaCorp Rx Inc. SectorCanada

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

-

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

PharmaCorp Rx Inc. SectorCanada

Global Valuation

-

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

PharmaCorp Rx Inc. SectorCanada

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

PharmaCorp Rx Inc. SectorCanada

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

-

Rating Revisions

PharmaCorp Rx Inc. SectorCanada

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
62.45M - - - -
15.83B
AA
7.38B
AA
6.21B
AAA
3.98B
AAA
3.3B
BBB
3.12B
AAA
2.95B
BB
2.62B - - - - -
2.78B -
BBB
- -
Average 4.82B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PCRX Stock
  4. Ratings PharmaCorp Rx Inc.